Rapid Discovery for Targeted Therapies in Oncology
More than 80% of the world's oceans remain unexplored, this vast resource contains the keys for untold discoveries.
Ocean Therapeutics has unlocked the door to rapid drug discovery utilizing novel compounds found in the ocean.
Together with researchers at the Scripps Institution of Oceanography, our founders explored seabed sediments found near remote islands in the Pacific.
Their discovery of an unknown bacterium led to the discovery of Seriniquinone, a novel chemotype active against a select number of cancer cells.
Building on this discovery, Ocean Therapeutics has developed a groundbreaking platform to greatly accelerate the process of drug discovery saving hundreds of millions of dollars and getting life-saving medicine into the hands of patients faster.
Using our proprietary validated compound platform, Ocean Therapeutics has access to a 200,000-novel library of novel chemotypes.
While our compounds significantly affect multiple cell lines, our first target is Melanoma.
Current therapies are ineffective for many melanoma patients.
Nearly 50% of Melanoma patients fail to respond to current treatments or become resistant to the treatment over time, especially those with Stage IV and distant metastasis.
Tested against the NCI-60 Human Tumor Cell Lines, SQ demonstrates strong in vitro growth inhibition of all melanoma tumor cell lines, among others.
While highly promising, our work is not limited to Melanoma.
With our novel platform of 200,000 unique molecules, unavailable from other sources, we will continue our journey to discover new cancer therapeutics.
